Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
M. Campioni, I. Agirrezabal, R. Hajek, J. Minarik, L. Pour, I. Spicka, S. Gonzalez-McQuire, P. Jandova, V. Maisnar
| Year of publication: |
2020
|
|---|---|
| Authors: | Campioni, M. ; Agirrezabal, I. ; Hájek, Roman ; Minarik, J. ; Pour, L. ; Spicka, I. ; Gonzalez-McQuire, S. ; Jandova, P. ; Maisnar, V. |
| Published in: |
The European journal of health economics : HEPAC ; health economics in prevention and care. - Berlin : Springer, ISSN 1618-7598, ZDB-ID 2045253-6. - Vol. 21.2020, 2, p. 219-233
|
| Subject: | Carfilzomib | Multiple myeloma | Cost-effectiveness | Real world | ASPIRE | Registry of Monoclonal Gammopathies |
| Type of publication: | Article |
|---|---|
| Type of publication (narrower categories): | Aufsatz in Zeitschrift ; Article in journal |
| Language: | English |
| Other identifiers: | 10.1007/s10198-019-01122-6 [DOI] |
| Source: | ECONIS - Online Catalogue of the ZBW |
Persistent link: https://www.econbiz.de/10012221946